Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BLU-782 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single ascending doses with BLU-782 | EXPERIMENTAL | - |
| Single ascending doses with placebo | PLACEBO_COMPARATOR | - |
| Multiple ascending doses with BLU-782 | EXPERIMENTAL | - |
| Multiple ascending doses with placebo | PLACEBO_COMPARATOR | - |
| Food effect of BLU-782 taken with food | EXPERIMENTAL | - |
| Food effect of BLU-782 taken without food | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BLU-782 | DRUG | oral capsules |
| Placebo | DRUG | oral capsules |
| BLU-782 taken with food | DRUG | oral capsules |
Inclusion Criteria: * Medically healthy * Non-smoker * Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2 * No clinically significant cardiac history * No current electrocardiogram (ECG) abnormality * Female must not be of childbearing potential Exclusion Criteria: * History of or current mental or legal ...
BLU-782 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is currently in Phase 1 clinical development. The only completed trial evaluated its safety, tolerability, pharmacokinetics, and food effect in healthy adults.
BLU-782 is being developed by Blueprint Medicines Corporation, a biopharmaceutical company traded on the Nasdaq under the ticker symbol BPMC. The company conducted a Phase 1 trial of BLU-782 in healthy volunteers in the United States.
BLU-782 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The single Phase 1 trial, NCT03858075, has been completed.
BLU-782 has one completed clinical trial, NCT03858075, titled "Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults." This Phase 1 study enrolled 108 healthy volunteers in the United States and was placebo-controlled and double-blind.
BLU-782 is not FDA approved. It is an investigational small molecule that has completed a Phase 1 trial in healthy volunteers. Its safety and efficacy have not been established for any medical condition, and it remains in clinical development.